Navigation Links
IDM Pharma Receives Notification from NASDAQ Relating to Minimum Bid Price
Date:2/5/2008

On February 5, 2008, the closing price of the Company's common stock was

$3.81 per share

IRVINE, Calif., Feb. 5 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) today announced that it received a letter, dated February 4, 2008, from The NASDAQ Stock Market, notifying IDM Pharma that during the preceding 30 consecutive business days, the closing bid price of the Company's common stock had been below the $1.00 minimum bid per share required for continued listing on the NASDAQ Global Market under NASDAQ Marketplace Rule 4450(a)(5).

The NASDAQ letter dated February 4, 2008 has no immediate effect on the listing of the Company's common stock. On February 5, 2008, the closing price of the Company's common stock was $3.81 per share.

In accordance with NASDAQ Marketplace Rule 4450(e)(2), the Company will be granted 180 calendar days, or until August 4, 2008, to regain compliance with the minimum bid price requirement in accordance with NASDAQ Marketplace Rule 4450(a)(5) by maintaining a closing bid price of $1.00 per share or higher for a minimum of 10 consecutive trading days. If the Company is successful in meeting this requirement, NASDAQ will provide written notification that is has achieved compliance with the Rule. If the Company is unsuccessful in meeting the minimum bid requirement during this initial 180-day period, NASDAQ will provide notice to IDM Pharma that the Company's common stock will be delisted from the NASDAQ Global Market. If the Company receives a delisting notification, the Company may appeal to the Listing Qualifications Panel or apply to transfer its common stock to the NASDAQ Capital Market if IDM Pharma satisfies all criteria for initial listing on the NASDAQ C
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. West Pharmaceutical Services to Present at the 2008 UBS Global Healthcare Services Conference
2. MAP Pharmaceuticals Announces Resignation of Chief Medical Officer
3. ADVENTRX Pharmaceuticals to Present at The 10th Annual BIO CEO & Investor Conference
4. ARMSRx Tackles the New Rx Addiction -- Pharmacy Benefit Audits
5. NPS Pharmaceuticals to Present at BIO CEO & Investor Conference
6. USP publishes Spanish edition of United States Pharmacopeia and National Formulary
7. Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
8. Poniard Pharmaceuticals Announces Upcoming Conference Participation
9. Akela Pharma receives letter from the FDA regarding its pre-clinical toxicology studies for Fentanyl TAIFUN(R)
10. Simcere Pharmaceutical Group to Announce Fourth Quarter 2007 Earnings on Tuesday, March 4, 2008
11. Webcast Alert: Oscient Pharmaceuticals Announces Date for Release of Fourth Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... has found that India,s shocking rates of suicide are ... are clinging to tiny smallholdings less than one ... as cotton and coffee, that are highly susceptible to ... of previous case studies that point to a crisis ... ,liberalisation, of the nation,s economy during the 90s. Researchers ...
(Date:4/17/2014)... adrenaline after they suffer a cardiac arrest outside of ... long-term, according to new research conducted at St. Michael,s ... a cardiac arrest get adrenaline, which has been the ... Dr. Steve Lin, an emergency physician and trauma team ... treatment, long-term survival rates of patients who suffer a ...
(Date:4/17/2014)... that lost its status as the leading weapon against ... of life, with new research indicating it simply needs ... the use of the cheap anti-malarial drug chloroquine in ... lives of more than half a million people each ... malaria has developed resistance to chloroquine, but research carried ...
(Date:4/16/2014)... , STANFORD, Calif. Consider the marvel of the embryo. ... shape and function as they multiply to become the cells ... tissues of the body. , Now, in a feat of ... the complex genetic coding that allows embryonic cells to proliferate ...
(Date:4/16/2014)... 2014): Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today ... CDX-1401 in solid tumors, including long-term patient follow-up, have ... 6 Issue 232). The data demonstrate robust antibody and ... patients with very advanced cancers and suggest that CDX-1401 ...
Breaking Medicine News(10 mins):Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:Scientists find new way to fight malaria drug resistance 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4
... ... new book “A must have...The Maroema Cook Book” by Mamta Reid of Tokyo’s MAROEMA Vegetarian ... (PRWEB) May 6, ... new inspiration with the release of “A must have...The Maroema Cook Book” by Mamta Reid. ...
... heart disease and stroke rates in China will rise ... aging population and other increased risk factors, without policies ... smoking, according to research from Columbia University Medical Center ... an American Heart Association journal. "China,s standard of ...
... events , WEDNESDAY, May 5 (HealthDay News) -- A ... significantly cuts down on hospital drug errors, researchers from ... "We had the opportunity to design and implement a ... the hospital gets the right medication at the right ...
... Researchers at the University of Toronto have discovered a ... number of genes to generate enormously complex organs such as ... in the journal Nature entitled "Deciphering the Splicing ... Benjamin Blencowe of the University of Toronto describes how a ...
... Nausea in pregnant women tends to fade after the ... it can be a sign of flu, researchers at UT ... women who sought medical care. "People don,t necessarily think ... vomiting, but our study showed that they are common with ...
... finds , WEDNESDAY, May 5 (HealthDay News) -- People who,ve ... face an increased risk for heart complications and death if ... study has found. , "We looked at the risks connected ... Nicholas L.M. Cruden, a former cardiology lecturer at the University ...
Cached Medicine News:Health News:Unique and Nutritious Vegetarian Recipes Featured in Newly Released Hand-Bag Friendly “A must have...The Maroema Cook Book” 2Health News:Unique and Nutritious Vegetarian Recipes Featured in Newly Released Hand-Bag Friendly “A must have...The Maroema Cook Book” 3Health News:China facing public health crisis with projected increase in cardiovascular disease by 2030 2Health News:China facing public health crisis with projected increase in cardiovascular disease by 2030 3Health News:Bar Codes Cut Down on Hospital Medication Errors 2Health News:Bar Codes Cut Down on Hospital Medication Errors 3Health News:U of T researchers crack 'splicing code,' solve a mystery underlying biological complexity 2Health News:Nausea and speeding heart can be signs of flu in pregnant women 2Health News:Risks Rise for Other Surgeries After Stent Implants 2
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... and Market Analysis to 2022 ... Dermatitis - India Drug Forecast and Market ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... YORK, Oct. 17, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0487169/Novo-Nordisk-A/S-PharmaVitae-Profile.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory ... the historical and forecast performance for Novo ...
... Inc. (NASDAQ: ANDS ) today announced that it has ... (SIX: RO, ROG; OTCQX: RHHBY). Under the terms of the merger ... outstanding shares of common stock of Anadys at USD 3.70 per ... represents a 256% premium over the closing price of USD 1.04 ...
Cached Medicine Technology:Novo Nordisk A/S: PharmaVitae Profile 2Anadys Announces Agreement To Be Acquired By Roche 2Anadys Announces Agreement To Be Acquired By Roche 3Anadys Announces Agreement To Be Acquired By Roche 4
... Acid is a non-irritating rapid exfoliator. Lactic Acid ... to peel and exfoliating agents in skin care ... other exfoliators for a long period and want ... occurring human metabolite, and combined with the chemical ...
... is available in two innovative formulations: Level ... active). The Level I (40% active) formulation ... extract, which DCL scientists have identified and ... and calm the skin while the beneficial ...
... CosmoDerm and CosmoPlast are dermal fillers ... acne scars and other soft tissue contour ... of the lip border. The collagen in ... dermal tissue that is grown under controlled ...
... is a gel of ... species of bacteria, chemically ... suspended in phosphate,buffered saline ... and concentration of 20 ...
Medicine Products: